Stratec SE (0RAR)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 23.07 |
|---|---|
| 52-week range | 15.80 – 28.48 |
| Return, 1 month / 3 months | −2.4% / +21.3% |
| Return, 1 year / 3 years | −18.2% / −50.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 49 |
| Volatility (1 year) | 39.9% |
| Worst drawdown (1 year) | -43.0% |
| Average daily value traded | 0.23M EUR |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Stratec SE designs and builds automated instruments and systems used in laboratory diagnostics. The company develops analysers, sample-handling equipment and related components for in-vitro diagnostics, serving diagnostics companies and clinical laboratories that need reliable automation for testing. Its work spans instrument development, manufacturing and integration of the electronics and software that run these systems. Stratec is based in Birkenfeld, Germany, and supplies customers in the diagnostics and life-science markets.
On this site Stratec SE appears as a stock on the London Exchange (UK), code 0RAR, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Stratec SE (0RAR) trades on the London Exchange in UK. It last closed at EUR 23.07 on 21 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,788 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.2% and over the last three months it rose 21.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.7% | ||
| From 52-week high | -17.0% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 21.3% | ||
| 6-month return | 21.5% | ||
| 12-month return, skipping the last month | -16.2% | ||
| Stability (higher is calmer) | 34 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.0% | ||
| Liquidity | 37 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.23M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.9% |
|---|---|
| 1 month | −2.4% |
| 3 months | +21.3% |
| 6 months | +21.5% |
| 1 year | −18.2% |
| 3 years | −50.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 23.28 / 19.94 |
|---|---|
| Golden / death cross (60 days) | Golden, 41 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.73 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Jun 2026 | EUR 0.6000 |
| 30 Jun 2025 | EUR 0.6000 |
| 20 May 2024 | EUR 0.5500 |
| 18 May 2023 | EUR 0.9700 |
| 23 May 2022 | EUR 0.9500 |
| 21 May 2021 | EUR 0.9000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.